Casi Pharmaceuticals Inc Stock Price, News & Analysis

CASI Pharmaceuticals (NASDAQ:CASI) has appointed Dr. Barbara Krebs-Pohl as an Independent Director to its Board of Directors. Dr. Krebs-Pohl brings 27 years of biotechnology experience, notably serving as Chief Business Officer at MorphoSys where she led its $2.9B acquisition by Novartis. She also played key roles in significant transactions including Constellation Pharmaceuticals' acquisition by MorphoSys and HI-Bio's $1.8B acquisition by Biogen.

The appointment comes at a crucial time following CASI's recent FDA IND acceptance for CID-103, their antibody-mediated rejection treatment. Dr. Krebs-Pohl currently serves as Managing Director of the Foundation for Stem Cell Research and Regenerative Medicine and as Partner at Viopas Venture Consulting.

CASI Pharmaceuticals (NASDAQ:CASI) reported its Q2 2025 financial results and business updates. The company achieved $4.2 million in revenue, a 5% year-over-year increase. Key developments include FDA clearance for CID-103's IND application in renal allograft antibody-mediated rejection (AMR) and ongoing Phase 1/2 trials in immune thrombocytopenic purpura (ITP).

CASI entered a significant $20 million Equity and Assets Transfer Agreement with Kaixin Pharmaceuticals, involving the sale of Chinese subsidiaries and certain regional rights for pipeline products. The company appointed David Cory as CEO and reported a net loss of $13.4 million for Q2 2025, with cash reserves declining to $6.7 million from $13.5 million in December 2024.

CASI Pharmaceuticals (NASDAQ:CASI), a clinical-stage biopharmaceutical company specializing in therapies for organ transplant rejection and autoimmune diseases, has announced its participation in the upcoming Cantor Global Healthcare Conference.

CEO David Cory will engage in a fireside chat on September 3, 2025, at 11:30 AM ET in New York City. The company will also conduct one-on-one investor meetings during the conference. Investors can access the live webcast through CASI's website, with a replay available for 90 days following the event.

CASI Pharmaceuticals (NASDAQ:CASI) has received FDA clearance for its Investigational New Drug (IND) application for CID-103, a potential best-in-class anti-CD38 monoclonal antibody targeting renal allograft antibody-mediated rejection (AMR). The company plans to initiate a Phase 1 clinical trial to evaluate the safety, tolerability, and efficacy of CID-103 in adults with active and chronic active renal allograft AMR.

AMR is identified as a leading cause of kidney transplant failure, often resulting in dialysis or repeat transplantation. The Phase 1 study will focus on dose-ranging and safety assessments, addressing an urgent medical need in transplant medicine where current treatment options are limited.

CASI Pharmaceuticals (NASDAQ:CASI) has appointed David Cory as its new Chief Executive Officer and Board member, while former CEO Wei-Wu He transitions to Executive Chairman. Cory brings over 30 years of operational experience in biotech and pharma, with a track record of raising over $1B in capital markets and multiple successful company exits.

The appointment aims to focus CASI's U.S. operations on developing CID-103, a potential best-in-class anti-CD38 monoclonal antibody. The drug is currently in Phase 1/2 trials for chronic immune thrombocytopenia (ITP), with an IND submitted for trials in renal allograft antibody-mediated rejection (AMR).

Cory's previous roles include CEO positions at LIB Therapeutics and Eiger BioPharmaceuticals, where he led successful drug developments and regulatory approvals. His experience spans startups like InterMune and CoTherix, which saw collective exits of approximately $9 billion.

CASI Pharmaceuticals (NASDAQ: CASI) has announced it will host a live conference call and webcast on Wednesday, May 21, 2025, at 8:00 a.m. PT/11:00 a.m. ET to provide business and clinical updates. The biopharmaceutical company, which focuses on developing and commercializing innovative therapeutics and pharmaceutical products, will make presentation materials available in the Investors section of their website following the conference call.

CASI Pharmaceuticals (NASDAQ:CASI) reported its Q1 2025 financial results and significant business updates. The company achieved revenue of $6.2 million, an 82% increase from $3.4 million in Q1 2024. However, CASI reported a net loss of $10.8 million, up 14% from the previous year. The company announced a major strategic move, entering into a $20 million Equity and Assets Transfer Agreement with Kaixin Pharmaceuticals to sell its Chinese subsidiaries and certain product rights. In clinical developments, CASI dosed the first patient in the third cohort of its Phase 1/2 study for CID-103 at 300mg for chronic immune thrombocytopenia. The company's cash position stood at $10.9 million as of March 31, 2025, down 19% from December 2024.

CASI Pharmaceuticals (NASDAQ:CASI) has announced a significant asset divestiture in China through a definitive Equity and Assets Transfer Agreement with Kaixin Pharmaceuticals, owned by CASI's Chairman and CEO Dr. Wei-Wu He. The $20 million transaction includes the sale of 100% equity interests in two Chinese subsidiaries and the transfer of licensing rights for BI-1206, CID-103, and Thiotepa in specific Asian regions.

The deal involves the assumption of up to $20 million in company debt and requires certain conditions to be met, including resolving judicial freezes on the target equity interests. Post-transaction, CASI will retain rights to CID-103 in Japan and non-Asian regions, EVOMELA®, FOLOTYN®, CNCT19, and CB-5339, focusing on developing CID-103 for organ transplant rejection and autoimmune diseases.

CASI Pharmaceuticals (NASDAQ:CASI) has received a deficiency notice from Nasdaq on May 5, 2025, for failing to maintain the minimum Market Value of Listed Securities (MVLS) requirement of $35 million. The company's MVLS fell below the threshold for 30 consecutive business days from March 20 to May 2, 2025. CASI has been granted a 180-day compliance period until November 3, 2025, to regain compliance by maintaining an MVLS of $35 million or above for at least 10 consecutive business days. The company also does not meet alternative Nasdaq listing requirements. While CASI's securities continue to trade on Nasdaq, failure to regain compliance could result in delisting.